Ovary Neoplasms
5
0
1
1
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
9 treatments under study, led by Cisplatin Ckm Celecoxib Dc Vaccine
Research Leaders
8 sponsors active, led by National Cancer Institute (NCI)
Related Conditions
Often studied with 19 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
20.0%
1 terminated out of 5 trials
50.0%
-36.6% vs benchmark
20%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
Research Network
Common Treatments
- Cisplatin Ckm Celecoxib Dc Vaccine1
- Hipec1
- Cisplatin Celecoxib Dc Vaccine1
- Fenretinidelxs Ketoconazole1
- Eortc Qlqov28 Questionnaire1
Active Sponsors
- National Cancer Institute (NCI)1
- Xi'an Jiaotong University1
- AIM ImmunoTech Inc.1
- Roswell Park Cancer Institute1
- Centre Oscar Lambret1
Top Investigators
Centre Oscar Lambret, Lille, France
Washington University School of Medicine
Texas Tech University Health Sciences Center
University of Pittsburgh
University of Texas Southwestern Medical Center
Related Conditions
- Ovarian Cancer5
- Cancer Of The Ovary4
- Cancer Of Ovary4
- Ovary Cancer3
- Neoplasms Ovarian3